---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-027984"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:55:29.768798+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings discloses Pexa-Vec license talks and potential SillaJen controlling stake

## Summary
- Vaximm in active negotiations with SillaJen to license Pexa-Vec, a Phase 2 oncolytic immunotherapy for renal cell carcinoma.
- OSR Holdings held preliminary verbal talks to acquire ~16% controlling stake in SillaJen (KOSDAQ:215600).
- No binding term sheet, letter of intent, or definitive agreement exists for either matter.
- Disclosed to comply with Regulation FD after inadvertent reference during March 13 analyst call.

## SEC filing metadata
- accession: 0001213900-26-027984
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/0001213900-26-027984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390026027984/ea0281786-8k_osr.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-027984
- JSON: https://secwatch.observer/filing/0001213900-26-027984.json
- Plain text: https://secwatch.observer/filing/0001213900-26-027984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.